openPR Logo
Press release

Accu Holding AG: Ordinary Capital increase and further capital measures to increase shareholder's equity

04-04-2016 09:56 AM CET | Industry, Real Estate & Construction

Press release from: Accu Holding AG

Ordinary Capital increase and further capital measures to increase shareholder's equity by more than CHF 10 million

Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.
NOT FOR DISTRIBUTION IN THE UNITED STATES, UNITED KINGDOM OR THE EUROPEAN ECONOMIC AREA

• Exercise of subscription rights within the expected range
• Strengthening of the balance sheet through conversion of debt of CHF 5'379'953 into new shares
• Additional subscription commitments of 300'000 shares
• Placement of CHF 1.4 million from conditional capital with Atlas Capital Markets

Emmenbrücke, April 4th, 2016. Accu Holding AG (Accu) announces today, that in the ordinary capital increase existing shareholders of Accu have subscribed a total of 92'183 shares with a nominal value of CHF 10.00 at an issue price of CHF 11.50 per share. Those shares together with the debt to equity conversion of additional 467'817 new shares will increase shareholder equity of Accu from CHF 26'186'150.00 to CHF 31'786'150. First trading day of the new shares on SIX Swiss Exchange is scheduled for April 14th, 2016. Delivery against payment of new shares is foreseen for 15th April 2016.
New investors are expected to subscribe for an additional 300'000 new shares in the ordinary capital increase. If these subscriptions are not submitted in time, the majority shareholder of Accu will convert additional loans granted to Accu in the same magnitude into shares subsequent to the ordinary capital increase.

Besides these commitments, Atlas Capital Markets (press release 16th November 2015) has acquired /committed to CHF 1.4 million new shares through private placements.

Various strategic investors have expressed their interest to invest in Accu. However, due to time constraints of the investment process, their commitments could not be obtained in the course of the ordinary capital increase. These investors are intended to participate via issuance of new shares out of authorized or conditional capital of Accu at a later stage.

Legal Disclaimer

The economic projections and predictions contained in this information relate to future facts. Such projections and predictions are subject to risks, uncertainties and changes which cannot be foreseen and which are beyond the control of Accu Holding AG. Accu Holding AG is therefore not in a position to make any representations as to the accuracy of economic projections and predictions or their impact on the financial situation of Accu Holding AG or the market in the securities of Accu Holding AG.

This document does not constitute an offer or invitation to subscribe for or purchase any securities. It is not being issued in countries where the public dissemination of the information contained herein may be restricted or prohibited by law. In particular, this document is not being issued in the United States of America and should not be distributed to U.S. persons or publications with a general circulation in the United States. Any non-compliance with such restrictions may result in a n infringement of U.S. securities laws. Securities of Accu Holding AG ('Company') are not being publicly offered outside of Switzerland. In particular, the securities of the company have not been registered under the U.S. securities laws and may not be offered, sold or delivered within the United States or to U.S. persons absent the registration under or an applicable exemption from the registration requirements of the U.S. securities laws. This document does not constitute a prospectus according to 652a or article 1156 of the Swiss Code of Obligations or article 27et seq. of the Six Swiss Exchange listing rules.

This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order') or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'Relevant Persons'). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents.

Accu Holding AG - Company Profile

The Accu Holding AG is listed on the SIX Swiss Exchange with its headquarter in Emmenbrücke/Lucerne. It focuses on the two business areas 'Industrial Yarns' and 'Surface Technology' and investing in leading technology companies that operate in attractive market niches in Europe, Asia and America. Industrial yarns encompasses the development and manufacturing of yarns based on polymer and polyamide. These yarns are used in applications such as mechanical rubber goods (MRG) such as conveyor belts, hoses and transmission belts, as well as for the production of ropes and nets used for example in the manufacture of airbags and tires. The business unit of surface technology includes the equipment manufacturer of heat treatment and coating equipment and the operation of heat treatment shops and high-tech thin-coating centres of the latest generation. These high-quality products are manufactured in Europe and the US for niche markets in the automotive, aerospace, medical, petroleum, process and manufacturing industries.

Contact:

Andreas Kratzer
Accu Holding AG
Gerliswilstrasse 17
6020 Emmenbrücke
a.kratzer@accuholding.ch
Telefon +41 44 318 88 00

Media contact for Germany
edicto GmbH
Dr. Sönke Knop/Elke Pfeifer
Eschersheimer Landstraße 42
60322 Frankfurt am Main
Tel.: +49 69 905 505 51
E-Mail: sknop@edicto.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Accu Holding AG: Ordinary Capital increase and further capital measures to increase shareholder's equity here

News-ID: 329847 • Views: 700

More Releases from Accu Holding AG

Accu Holding AG: Shareholders approve all motions at Extraordinary General Meeti …
NOT FOR DISTRIBUTION IN THE UNITED STATES, UNITED KINGDOM OR THE EUROPEAN ECONOMIC AREA Accu Holding AG: Shareholders approve all motions at Extraordinary General Meeting - Subscription period begins as of the 18th of March 2016 Emmenbrücke, March 16, 2016 - Representing 70.77% of the company's share capital, the attending shareholders have today approved all motions of the Board of Directors at the extraordinary general assembly of Accu Holding AG. The proposal
Accu Holding strengthens the balance sheet, confirms guidance 2015 and gives out …
NOT FOR DISTRIBUTION IN THE UNITED STATES, UNITED KINGDOM OR THE EUROPEAN ECONOMIC AREA Accu Holding strengthens the balance sheet, confirms guidance 2015 and gives outlook 2016 - Planed capital increase to strengthen the balance sheet and reduce liabilities - Preliminary numbers 2015: Sales increase to CHF 156m from CHF 132.9m - Increase of EBITDA and net income versus previous year - Guidance 2016: Continued positive operational performance - Secondary listing of Accu shares
Invitation to the extraordinary general assembly of Accu Holding on 16 March 201 …
NOT FOR DISTRIBUTION IN THE UNITED STATES, UNITED KINGDOM OR THE EUROPEAN ECONOMIC AREA Emmenbrücke, February 24, 2016 - Accu Holding AG (Accu), a leading company in the field of industrial yarns and surface technology, invites its shareholders to an extraordinary shareholders meeting to be held in Lucerne. The meeting has been postponed from March 15th to March 16th 2016, i.e. one day later than announced on February 17th. The invitation

All 4 Releases


More Releases for CHF

Congestive Heart Failure (CHF) Treatment Devices Market Revenue Sizing Outlook A …
Allied Market Research added new research on Global Congestive Heart Failure (CHF) Treatment Devices Market- Global Opportunity Analysis and Industry Forecast, 2022-2030. The Congestive Heart Failure (CHF) Treatment Devices market explores comprehensive study on various segments like size, share, development, innovation, sales and overall growth of major players. The research is based on primary and secondary data sources and it consists both qualitative and quantitative detailing. Some of the key
Chronic Heart Failure (CHF) Drugs Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Chronic Heart Failure (CHF) Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Chronic Heart Failure (CHF) Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global Chronic Heart Failure (CHF) Drugs Market 2020 by Manufacturers, Regions,
Screening Eagle raises CHF 55 million to protect the built world
Screening Eagle Technologies (SET), a cloud-based technology platform connecting sensors, software, and data for intelligent inspection of assets and infrastructure, is pleased to announce it has raised CHF 55 million in its first institutional round of equity funding. Switzerland - April 3, 2020 -- Screening Eagle is on a mission to protect the built world. Massive economic value is at risk from aging global infrastructure and construction birth defects in
Global Congestive Heart Failure (CHF) Market Status, Analysis, Growth Factor, Ap …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Congestive Heart Failure (CHF) Market Research Report 2018” provides an in-depth analysis of the Congestive Heart Failure (CHF) with the forecast of market size and growth. The analysis includes addressable market, market by volume, and market share by business type and by segment (external and in-house).The research study examines the
Congestive Heart Failure (CHF) Treatment Devices Market Latest Trends by 2024
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to
Congestive Heart Failure (CHF) Treatment Devices Market: Report Scope and Market …
Congestive Heart Failure (CHF) is a chronic condition of a body, which adversely affects the pumping efficiency of the cardiac muscles and the heart. It occurs due to accretion of fluid around the heart that may contribute towards ineffective pumping of the heart. This condition may result in shortness of breathing, swelling and weakness. Left-sided CHF is the more commonly noted than right-sided CHF. Left-sided CHF occurs due to